Increased MxA Protein Expression and Dendritic Cells in Spongiotic Dermatitis Differentiates Dermatomyositis from Eczema
Majid Zeidi
Scholar | Resident Pathology, Dermatopathology
Presented at: American College of Rheumatology
Date:
Views: 13
Summary: Background/Purpose: Dermatomyositis (DM) is conventionally characterized by interface
dermatitis (ID) on skin histopathology. A subset of patients with clinically diagnosed DM have skin
biopsies showing spongiotic dermatitis (SD), a histopathology more commonly seen in eczema.
Diagnosis of DM is challenging, with significant delays following initial presentation. Our goals
were as follows: 1) to identify the percentage of clinically diagnosed DM patients with skin
biopsies showing SD, 2) to identify cytokine and cell markers that can determine if a skin biopsy
showing SD is consistent with DM in a patient with clinical DM.
Methods: Biopsies from 10 DM patients with SD histopathology (DM-SD) were compared to
biopsies from 10 healthy controls, 10 patients with eczema, and 12 DM patients with ID
histopathology (DM-ID). Skin biopsies were stained by H&E and by immunohistochemistry for
MxA, IFN-β, CD11c (mDC), and BDCA2 (pDC). Mucin expression was assessed using Hale’s iron
colloidal stain. Cytokines and mucin were quantified as area percent and mean intensity. Cells
were quantified as mean number of cells per high power field. Fisher’s exact test was used to
compare baseline patient characteristics. One-way ANOVA with Bonferroni’s multiple comparison
test was used to compare protein expression between groups.
Results: 11 of 164 (6.7%) patients with a clinical diagnosis of DM at our tertiary care center were
identified as having SD. MxA, IFN-β, CD11c (mDC), and BDCA2 (pDC) protein expression was
significantly higher in DM-SD compared to eczema (p < 0.01) and healthy controls (p < 0.0001)
(Fig. 1, 2). Expression of MxA, IFN-β, and BDCA2 were not significantly different between DM-SD
and DM-ID (Fig. 1, 2). Eosinophils identified on H&E were not significantly different between DMSD and eczema patients, although both were significantly higher compared to healthy controls and DM-ID (p < 0.01) (Fig. 2). Mucin was not significantly different between eczema, DM-SD, and DM-ID, although all were significantly elevated compared to healthy controls (p < 0.0001).
Conclusion: MxA, IFN-β, CD11c (mDC), and BDCA2 (pDC) protein expression were significantly
higher in DM-SD compared to eczema skin lesions. These markers can therefore be helpful to
distinguish between DM-SD versus eczema.